Memorial Sloan Kettering Cancer Center;紀念斯隆-凱特林癌症中心
发明人:
ADUSUMILLI, Prasad, S.,SADELAIN, Michel
申请号：
HK19100414
公开号：
HK1258041A1
申请日:
2019.01.10
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.
